PTC Therapeutics Inc. (NASDAQ:PTCT) saw unusually-strong trading volume on Thursday . Approximately 1,582,644 shares changed hands during trading, an increase of 58% from the previous session’s volume of 1,004,598 shares.The stock last traded at $7.55 and had previously closed at $7.11.

Several equities analysts have recently weighed in on PTCT shares. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and set a $39.00 target price on shares of PTC Therapeutics in a report on Sunday, April 17th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of PTC Therapeutics in a report on Friday, May 6th. Jefferies Group reaffirmed a “hold” rating and set a $8.00 target price on shares of PTC Therapeutics in a report on Friday, May 6th. Cowen and Company reaffirmed a “hold” rating on shares of PTC Therapeutics in a report on Sunday, April 17th. Finally, Wedbush reaffirmed a “neutral” rating and set a $11.00 target price on shares of PTC Therapeutics in a report on Wednesday, March 23rd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $36.05.

The firm’s market cap is $255.41 million. The stock has a 50 day moving average of $7.40 and a 200 day moving average of $13.09.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.26) by $0.04. During the same period in the previous year, the company posted ($1.15) earnings per share. The firm earned $18.90 million during the quarter, compared to analyst estimates of $13.74 million. PTC Therapeutics’s revenue was up 152.0% compared to the same quarter last year. Equities analysts forecast that PTC Therapeutics Inc. will post ($4.93) earnings per share for the current year.

Several large investors recently added to or reduced their stakes in PTCT. Jennison Associates LLC boosted its stake in PTC Therapeutics by 5.9% in the fourth quarter. Jennison Associates LLC now owns 1,023,987 shares of the biopharmaceutical company’s stock valued at $33,177,000 after buying an additional 57,092 shares during the period. Marshall Wace LLP boosted its stake in PTC Therapeutics by 50.6% in the fourth quarter. Marshall Wace LLP now owns 44,410 shares of the biopharmaceutical company’s stock valued at $1,439,000 after buying an additional 14,926 shares during the period. Turner Investments L.P. bought a new stake in PTC Therapeutics during the fourth quarter valued at approximately $1,532,000. Pinnacle Associates Ltd. boosted its stake in PTC Therapeutics by 59.2% in the fourth quarter. Pinnacle Associates Ltd. now owns 380,092 shares of the biopharmaceutical company’s stock valued at $12,315,000 after buying an additional 141,322 shares during the period. Finally, Gratus Capital LLC boosted its stake in PTC Therapeutics by 9.7% in the fourth quarter. Gratus Capital LLC now owns 53,350 shares of the biopharmaceutical company’s stock valued at $1,729,000 after buying an additional 4,700 shares during the period.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.